research use only
Cat.No.S8568
|
In vitro |
DMSO
: 1 mg/mL
(2.1 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 474.60 | Formula | C26H34N8O |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1628256-23-4 | -- | Storage of Stock Solutions |
|
|
| Synonyms | Lerociclib | Smiles | CC(C)N1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6 | ||
| Targets/IC50/Ki |
CDK4
(Cell-free assay) 1 nM
CDK6
(Cell-free assay) 2 nM
CDK9
(Cell-free assay) 28 nM
|
|---|---|
| In vitro |
G1T38 is highly potent and selective for CDK4/cyclin D1 and CDK6/cyclin D3 over CDK1, CDK2, CDK5 and CDK7 and their respective binding partners. In vitro, this compound decreases RB1 phosphorylation, causes a precise G1 arrest, and inhibits cell proliferation in a variety of CDK4/6-dependent tumorigenic cell lines including breast, melanoma, leukemia, and lymphoma cells with EC50 concentrations as low as 23 nM. |
| In vivo |
In vivo, G1T38 treatment leads to equivalent or improved tumor efficacy compared to the first-in-class CDK4/6 inhibitor, palbociclib, in an ER+ breast cancer xenograft model. Furthermore, this compound accumulates in mouse xenograft tumors but not plasma, resulting in less inhibition of mouse myeloid progenitors than after palbociclib treatment. In larger mammals, this difference in pharmacokinetics allows for 28 day continuous dosing of this chemical in beagle dogs without producing severe neutropenia. |
References |
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | pRB(Ser807/811) / RB |
|
28418845 |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03455829 | Completed | Carcinoma Non-Small-Cell Lung|Lung Cancer|Non-small Cell Lung Cancer |
G1 Therapeutics Inc. |
March 29 2018 | Phase 1|Phase 2 |
| NCT02983071 | Active not recruiting | Carcinoma Ductal Breast|Breast Cancer|Breast Neoplasm |
G1 Therapeutics Inc. |
January 2017 | Phase 1|Phase 2 |
| NCT02821624 | Completed | Healthy Volunteers |
G1 Therapeutics Inc. |
May 2016 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.